KR20060097772A - 펜세린 및 그 유사체의 제조방법 - Google Patents
펜세린 및 그 유사체의 제조방법 Download PDFInfo
- Publication number
- KR20060097772A KR20060097772A KR1020067017072A KR20067017072A KR20060097772A KR 20060097772 A KR20060097772 A KR 20060097772A KR 1020067017072 A KR1020067017072 A KR 1020067017072A KR 20067017072 A KR20067017072 A KR 20067017072A KR 20060097772 A KR20060097772 A KR 20060097772A
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- compound
- alkyl
- reaction medium
- eserolin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims description 42
- 150000001875 compounds Chemical class 0.000 claims abstract description 64
- 239000012948 isocyanate Substances 0.000 claims abstract description 23
- 150000002513 isocyanates Chemical class 0.000 claims abstract description 22
- -1 physostigmine compound Chemical class 0.000 claims abstract description 16
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229960001697 physostigmine Drugs 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- 150000003839 salts Chemical class 0.000 claims description 30
- 125000000217 alkyl group Chemical group 0.000 claims description 27
- 239000012429 reaction media Substances 0.000 claims description 22
- 239000002585 base Substances 0.000 claims description 21
- 239000003960 organic solvent Substances 0.000 claims description 19
- 239000002253 acid Substances 0.000 claims description 11
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 239000012431 aqueous reaction media Substances 0.000 claims description 9
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical group [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims description 8
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical group COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 5
- 239000012736 aqueous medium Substances 0.000 claims description 5
- 229910052783 alkali metal Inorganic materials 0.000 claims description 4
- 150000005215 alkyl ethers Chemical class 0.000 claims description 4
- 230000003301 hydrolyzing effect Effects 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical group O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 8
- 239000003021 water soluble solvent Substances 0.000 claims 5
- 150000003873 salicylate salts Chemical group 0.000 claims 2
- 229910000000 metal hydroxide Inorganic materials 0.000 claims 1
- 239000003799 water insoluble solvent Substances 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 230000007062 hydrolysis Effects 0.000 abstract description 4
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 26
- 239000011541 reaction mixture Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical class C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 10
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
- 239000002002 slurry Substances 0.000 description 8
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- 125000000753 cycloalkyl group Chemical group 0.000 description 6
- 239000012458 free base Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000006356 dehydrogenation reaction Methods 0.000 description 5
- 150000007522 mineralic acids Chemical class 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 150000007530 organic bases Chemical class 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical class COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 150000004703 alkoxides Chemical class 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 0 CC12C3=CC(OC(N*)=O)=CCC3N(*)C1N(*)CC2 Chemical compound CC12C3=CC(OC(N*)=O)=CCC3N(*)C1N(*)CC2 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- KLKFAASOGCDTDT-UHFFFAOYSA-N ethoxymethoxyethane Chemical compound CCOCOCC KLKFAASOGCDTDT-UHFFFAOYSA-N 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960002516 physostigmine salicylate Drugs 0.000 description 2
- HZOTZTANVBDFOF-PBCQUBLHSA-N physostigmine salicylate Chemical compound OC(=O)C1=CC=CC=C1O.C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C HZOTZTANVBDFOF-PBCQUBLHSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- PKRSYEPBQPFNRB-UHFFFAOYSA-N 2-phenoxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1OC1=CC=CC=C1 PKRSYEPBQPFNRB-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 150000001913 cyanates Chemical class 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical group [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000004714 phosphonium salts Chemical group 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- OGHBATFHNDZKSO-UHFFFAOYSA-N propan-2-olate Chemical compound CC(C)[O-] OGHBATFHNDZKSO-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical group 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 150000003628 tricarboxylic acids Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims (24)
- 제 1 항에 있어서, 상기 반응 매질은 불활성 수불용성 유기 용매를 함유하는 것을 특징으로 하는 방법.
- 제 2 항에 있어서, 상기 R은 메틸인 것을 특징으로 하는 방법.
- 제 3 항에 있어서, 상기 화학식 I의 화합물은 염인 것을 특징으로 하는 방법.
- 제 4 항에 있어서, 상기 염은 살리실레이트 염인 것을 특징으로 하는 방법.
- 제 5 항에 있어서, 상기 알칼리 금속 히드록시드는 수산화나트륨인 것을 특징으로 하는 방법.
- 제 2 항에 있어서, 상기 수불용성 용매는 C2 -6 알킬에테르인 것을 특징으로 하는 방법.
- a) pH 12 내지 14에서 하기 화학식 I의 피소스티그민 화합물 또는 그염을 수용성 용매가 존재하지 않는 수성 반응 매질에서 알칼리 금속 히드록시드로 가수분해하여 상기 수성 반응 매질에서 하기 에세롤린 화합물을 형성시키는 단계; 및b) 상기 반응 매질을 pH 8 내지 9.5로 조정하고, 에세롤린 화합물을 상기 조 정된 반응 매질로부터 추출하는 단계를 포함하는, 하기 화학식 Ⅱ의 정제된 에세롤린 화합물을 제조하는 방법:[화학식 Ⅱ]상기 화학식 Ⅱ에서, R은 독립적으로 C1 -6 알킬이다;[화학식 I]상기 화학식 I에서 R은 독립적으로 C1 -6 알킬이다.
- 제 8 항에 있어서, 상기 조정은 알칼리 금속 바이설파이트의(bisulfite) 부가에 의해 수행되는 것을 특징으로 하는 방법.
- 제 9 항에 있어서, 수성 매질은 불활성 수불용성 유기 용매를 함유하는 것을 특징으로 하는 방법.
- 제 10 항에 있어서, 상기 유기 용매는 C2 -6 알킬 에테르인 것을 특징으로 하는 방법.
- 제 11 항에 있어서, 피소스티그민 화합물은 산 부가염인 것을 특징으로 하는 방법.
- 제 12 항에 있어서, 상기 염은 살리실레이트 염인 것을 특징으로 하는 방법.
- a) 불활성 비양성자성 수용성 유기 용매를 함유하는 무수 반응매질에서 정제된 화학식 Ⅱ의 에세롤린 화합물을 유기 강염기로 처리하는 단계; 및b) 하기 펜세린 화합물을 형성시키기 위해 하기 화학식 Ⅳ의 이소시아네이트를 상기 반응 매질과 혼합함으로써 상기 처리된 에세롤린 화합물을 하기 화학식 Ⅳ의 이소시아네이트와 반응시키는 단계를 포함하는 화학식 Ⅲ의 펜세린 화합물을 제조하는 방법:[화학식 Ⅲ]상기 화학식 Ⅲ에서,R은 독립적으로 C1 -6 알킬이고;R1은 C3 -7 시클로알킬, 페닐, 페닐 C1 -6 알킬, 또는 C3 -7 시클로알킬 C1 -6 알킬이다;[화학식 Ⅱ]상기 화학식 Ⅱ에서, R은 독립적으로 C1 -6 알킬이다;[화학식 Ⅳ]R1-N=C=O상기 화학식 Ⅳ에서, R1은 C3 -7 시클로알킬, 페닐, 페닐 C1 -6 알킬, 또는 C3 -7 시클로알킬 C1 -6 알킬이다.
- 제 14 항에 있어서, 상기 수용성 용매는 디메톡시에탄인 것을 특징으로 하는 방법.
- 제 15 항에 있어서, 상기 유기 강염기는 부틸 리튬인 것을 특징으로 하는 방법.
- 제 15 항에 있어서, R은 메틸이고, 상기 이소시아네이트는 페닐이소시아네이트인 것을 특징으로 하는 방법.
- 제 14 항에 있어서, 펜세린 화합물의 형성 후에 상기 반응 매질에 물을 부가하여 반응 매질에서 형성된 펜세린 화합물을 침전시키는 단계를 더 포함하는 것을 특징으로 하는 방법.
- a) 하기 화학식 I의 피소스티그민 화합물 또는 그 염을 수용성 용매가 존재하지 않는 수성 반응 매질 중에서 알콕시드 금속 히드록시드로 pH 12 내지 14에서 가수분해하여, 상기 수성 반응 매질에서 하기 화학식 Ⅱ의 에세롤린 화합물을 형성시키는 단계;b) 상기 에세롤린 화합물을 함유하는 상기 반응 매질을 pH 8 내지 9.5로 조정하고 상기 조정된 수성 반응 매질로부터 상기 에세롤린 화합물을 순수한 형태로 추출하는 단계;c) 불활성의 비양성자성 수용성 유기 용매를 함유하는 무수 반응 매질에서 상기 정제된 에세롤린 화합물을 유기 강염기로 처리하는 단계;d) 하기 화학식 Ⅳ의 이소시아네이트를 상기 무수 반응 매질과 함께 혼합함 으로써 상기 처리된 에세롤린 화합물을 하기 화학식 Ⅳ의 이소시아네이트와 함께 반응시켜 펜세린 화합물을 형성시키는 단계를 포함하는 하기 화학식 Ⅲ의 펜세린 화합물 또는 그 염을 제조하는 방법:[화학식 Ⅲ]상기 화학식 Ⅲ에서, R은 독립적으로 C1 -6 알킬이고;R1은 C3 -7 시클로알킬, 페닐, 페닐 C1 -6 알킬, 또는 C3 -7 시클로알킬 C1 -6 알킬이다;[화학식 I]상기 화학식 I에서, R은 독립적으로 C1 -6 알킬이다;[화학식 Ⅱ]상기 화학식 Ⅱ에서, R은 상기한 바와같다;[화학식 Ⅳ]R1-N=C=O상기 화학식 Ⅳ에서, R1은 C3 -7 시클로알킬, 페닐, 페닐 C1 -6 알킬, 또는 C3 -7 시클로알킬 C1 -6 알킬이다.
- 제 19 항에 있어서, 상기 유기 강염기는 n-부틸 리튬인 것을 특징으로 하는 방법.
- 제 19 항에 있어서, 상기 수용성 용매는 디메톡시에탄인 것을 특징으로 하는 방법.
- 제 21 항에 있어서, R은 메틸이고 이소시아네이트는 페닐이소시아네이트인 것을 특징으로 하는 방법.
- 제 19 항에 있어서, 상기 펜세린 화합물의 형성 후에 물을 상기 무수 반응 매질에 부가하여 상기 펜세린 화합물을 침전시키는 단계를 더 포함하는 것을 특징으로 하는 방법.
- 제 19 항에 있어서, 상기 조정은 알칼리 금속 바이설파이트의 부가로 수행되는 것을 특징으로 하는 방법.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/042,586 | 2002-01-09 | ||
| US10/042,586 US6495700B1 (en) | 2002-01-09 | 2002-01-09 | Process for producing phenserine and its analog |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020047010683A Division KR100712003B1 (ko) | 2002-01-09 | 2002-12-11 | 펜세린 및 그 유사체의 제조방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20060097772A true KR20060097772A (ko) | 2006-09-15 |
Family
ID=21922704
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020067017072A Ceased KR20060097772A (ko) | 2002-01-09 | 2002-12-11 | 펜세린 및 그 유사체의 제조방법 |
| KR1020047010683A Expired - Fee Related KR100712003B1 (ko) | 2002-01-09 | 2002-12-11 | 펜세린 및 그 유사체의 제조방법 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020047010683A Expired - Fee Related KR100712003B1 (ko) | 2002-01-09 | 2002-12-11 | 펜세린 및 그 유사체의 제조방법 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6495700B1 (ko) |
| EP (1) | EP1463729B1 (ko) |
| JP (1) | JP2005514459A (ko) |
| KR (2) | KR20060097772A (ko) |
| CN (1) | CN1301995C (ko) |
| AT (1) | ATE466015T1 (ko) |
| AU (1) | AU2002353102B2 (ko) |
| BR (1) | BRPI0215492A2 (ko) |
| CA (1) | CA2470560C (ko) |
| DE (1) | DE60236207D1 (ko) |
| HR (1) | HRP20040606A2 (ko) |
| HU (1) | HUP0500747A3 (ko) |
| IL (1) | IL162827A0 (ko) |
| PL (1) | PL374240A1 (ko) |
| WO (1) | WO2003059909A1 (ko) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004285893B2 (en) | 2003-10-21 | 2011-12-15 | Colucid Pharmaceuticals, Inc. | Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents |
| WO2006138385A2 (en) * | 2005-06-14 | 2006-12-28 | Cancog Technologies Inc.24 | Use of phenserine and analogs to treat behavioral problems and improve trainability |
| EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| AU2006282896A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| US7998971B2 (en) * | 2006-09-08 | 2011-08-16 | Braincells Inc. | Combinations containing a 4-acylaminopyridine derivative |
| CN102905532A (zh) | 2010-02-09 | 2013-01-30 | 约翰斯.霍普金斯大学 | 用于改善认知功能的方法和组合物 |
| US20120225922A1 (en) | 2011-03-04 | 2012-09-06 | Qr Pharma | Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration |
| US20130096316A1 (en) * | 2011-10-14 | 2013-04-18 | Qr Pharma, Inc. | Novel Method for Preparation of Bisnorcymerine and Salts Thereof |
| EP3610890A1 (en) | 2012-11-14 | 2020-02-19 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| EP2968237A4 (en) | 2013-03-15 | 2016-08-31 | Univ Johns Hopkins | METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION |
| CN105142623A (zh) | 2013-03-15 | 2015-12-09 | 艾吉因生物股份有限公司 | 用于改善认知功能的方法和组合物 |
| US10159648B2 (en) | 2015-05-22 | 2018-12-25 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
| CA2994974C (en) | 2015-08-14 | 2024-04-09 | Qr Pharma | Methods of treatment or prevention of acute brain or nerve injuries |
| WO2018217892A1 (en) | 2017-05-24 | 2018-11-29 | Qr Pharma, Inc. | Prevention or treatment of disease states due to metal dis-homeostasis via administration of posiphen to healthy or sick humans |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1109003B (it) * | 1977-09-20 | 1985-12-16 | Univ Firenze | Derivati dell 1 2 3 8 3 a 8 a esai dropirrolo 23 b indolo |
| IT1199076B (it) | 1984-03-01 | 1988-12-30 | Consiglio Nazionale Ricerche | Derivati della fisostigmina con proprieta'di inibizione della aceticolinesterasi e relativo procedimento di produzione |
| US5306825A (en) | 1984-03-01 | 1994-04-26 | Consiglio Nazionale Delle Ricerche | Physostigmine derivatives with acetylcholinesterase inhibition properties, and the relative production process |
| US4791107A (en) | 1986-07-16 | 1988-12-13 | Hoechst-Roussel Pharmaceuticals, Inc. | Memory enhancing and analgesic 1,2,3,3A,8,8A-hexahydro-3A,8 (and) 1,3A,8)-di(and tri)methylpyrrolo(2,3-B)indoles, compositions and use |
| IT1225462B (it) * | 1987-04-03 | 1990-11-14 | Mediolanum Farmaceutici Srl | Sali organici di derivati della fisostigmina |
| US5187165A (en) | 1987-05-15 | 1993-02-16 | Hoechst-Roussel Pharmaceuticals Inc. | Memory enhancing and analgesic 1,2,3a,8,8a-hexahydro-3a,8(and 1,3a,8)-di(and tri)methylpyrrolo[2,3-b]indoles |
| US4900748A (en) | 1988-03-04 | 1990-02-13 | The United States Of America As Represented By The Department Of Health And Human Services | Carbamates related to (-)-physostigmine as cholinergic agents |
| US5260452A (en) | 1989-11-03 | 1993-11-09 | Hoechst-Roussel Pharmaceuticals Inc. | 4- and 6-carbamates related to physostigmine and intermediates for the preparation thereof |
| US5077289A (en) | 1989-11-30 | 1991-12-31 | Hoechst Roussel Pharmaceuticals Inc. | Memory enhancing and analgesic aminocarbonylcarbamates related to physostigmine |
| US5177101A (en) | 1989-11-30 | 1993-01-05 | Hoechst-Roussel Pharmaceuticals Incorporated | Memory enhancing and analgesic aminocarbonylcarbamates related to physostigmine |
| US5705657A (en) | 1991-02-14 | 1998-01-06 | Labochim Laboratorio Chimico Internazionale S.P.A. | Isocyanate process for the preparation of 1,3A,8-trimethyl-1,2,3,3A, 8, 8A-hexahydro-pyrrole 2,3-B! indol-5 (3AS, 8AR) -hepthylcarbamate |
| EP0499959A1 (en) | 1991-02-18 | 1992-08-26 | Bromine Compounds Ltd. | Process for the manufacture of substituted maleimides |
| JP3708957B2 (ja) | 1991-09-26 | 2005-10-19 | アメリカ合衆国 | (−)−エゼロリン、(−)−n1−ノルエゼロリンおよび(−)−n1−ベンジルノルエゼロリンの置換フェンゼリンおよびフェニルカルバミン酸塩:特異的アセチルコリンエステラーゼ阻害薬としての使用 |
| US5206260A (en) | 1991-11-07 | 1993-04-27 | Merck & Co., Inc. | Hexahydropyrrolo[2,3-b]indole derivatives |
| US5302721A (en) | 1992-07-21 | 1994-04-12 | Hoechst-Roussel Pharmaceuticals Incorporated | Method of preparation of physostigmine carbamate derivatives from eseretholes |
| FI990752A0 (fi) * | 1992-07-21 | 1999-04-06 | Hoechst Marion Roussel Inc | Menetelmä fysostigmiinikarbamaattijohdannaisten valmistamiseksi fysostigmiinistä |
| US5409948A (en) | 1992-11-23 | 1995-04-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method for treating cognitive disorders with phenserine |
| US5665880A (en) | 1996-10-31 | 1997-09-09 | Hoechst Marion Roussel, Inc. | Method of preparation of physostigmine carbamate derivatives from eseretholes |
| US5677457A (en) | 1996-12-19 | 1997-10-14 | Hoechst Marion Roussel, Inc. | Method of preparation of physostigmine carbamate derivatives from eseroline ethers |
-
2002
- 2002-01-09 US US10/042,586 patent/US6495700B1/en not_active Expired - Lifetime
- 2002-12-11 KR KR1020067017072A patent/KR20060097772A/ko not_active Ceased
- 2002-12-11 AT AT02790077T patent/ATE466015T1/de active
- 2002-12-11 KR KR1020047010683A patent/KR100712003B1/ko not_active Expired - Fee Related
- 2002-12-11 WO PCT/US2002/039537 patent/WO2003059909A1/en not_active Ceased
- 2002-12-11 CN CNB028269985A patent/CN1301995C/zh not_active Expired - Fee Related
- 2002-12-11 HR HRP20040606 patent/HRP20040606A2/hr not_active Application Discontinuation
- 2002-12-11 JP JP2003560012A patent/JP2005514459A/ja active Pending
- 2002-12-11 BR BRPI0215492A patent/BRPI0215492A2/pt not_active IP Right Cessation
- 2002-12-11 IL IL16282702A patent/IL162827A0/xx unknown
- 2002-12-11 PL PL02374240A patent/PL374240A1/xx unknown
- 2002-12-11 HU HU0500747A patent/HUP0500747A3/hu unknown
- 2002-12-11 EP EP02790077A patent/EP1463729B1/en not_active Expired - Lifetime
- 2002-12-11 AU AU2002353102A patent/AU2002353102B2/en not_active Ceased
- 2002-12-11 DE DE60236207T patent/DE60236207D1/de not_active Expired - Lifetime
- 2002-12-11 CA CA002470560A patent/CA2470560C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0500747A2 (hu) | 2005-11-28 |
| HUP0500747A3 (en) | 2009-05-28 |
| EP1463729A1 (en) | 2004-10-06 |
| DE60236207D1 (de) | 2010-06-10 |
| PL374240A1 (en) | 2005-10-03 |
| HK1075659A1 (en) | 2005-12-23 |
| IL162827A0 (en) | 2005-11-20 |
| EP1463729B1 (en) | 2010-04-28 |
| JP2005514459A (ja) | 2005-05-19 |
| CA2470560C (en) | 2007-05-15 |
| ATE466015T1 (de) | 2010-05-15 |
| BRPI0215492A2 (pt) | 2016-07-05 |
| CN1612880A (zh) | 2005-05-04 |
| KR100712003B1 (ko) | 2007-05-02 |
| HRP20040606A2 (en) | 2004-12-31 |
| US6495700B1 (en) | 2002-12-17 |
| WO2003059909A1 (en) | 2003-07-24 |
| AU2002353102B2 (en) | 2007-05-24 |
| KR20040072711A (ko) | 2004-08-18 |
| AU2002353102A1 (en) | 2003-07-30 |
| CN1301995C (zh) | 2007-02-28 |
| EP1463729A4 (en) | 2005-06-29 |
| CA2470560A1 (en) | 2003-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100712003B1 (ko) | 펜세린 및 그 유사체의 제조방법 | |
| CN109096122B (zh) | 制备亚精胺的方法 | |
| CN110637009B (zh) | 用于制备4-甲氧基吡咯衍生物的中间体的方法 | |
| JP2003512294A (ja) | β亜燐酸ニトロキシドラジカルの製造方法 | |
| AU693588B2 (en) | Novel process for the preparation of diisopinocampheylchloroborane | |
| JPH03236359A (ja) | 環状アミノ酸抗けいれん性化合物の改良製法 | |
| CN109053496B (zh) | 一种3-Boc-氨甲基环丁酮的合成方法 | |
| EP0432898B1 (en) | Glutaric acid derivatives and preparation thereof | |
| LV12073B (en) | METHOD OF RECOVERY OF DIOOPINOCAMPHENYLHORBORANA | |
| CN114539125B (zh) | 一种帕西洛韦中间体的合成方法 | |
| MXPA06015262A (es) | Proceso para preparar ((1(hidroximetil)-ciclopropil)oxi) metilfosfonato de di-isopropilo. | |
| US5260467A (en) | Glutaric acid derivatives and preparation thereof | |
| WO2023187833A1 (en) | A novel salt of bempedoic acid | |
| JP2002533334A (ja) | 抗ヒスタミン活性を有する三環式化合物を調製するためのプロセス | |
| KR950008527B1 (ko) | 피리딘 유도체의 제조방법 | |
| CN115181093A (zh) | Sunvozertinib中间体的制备方法 | |
| JP2005145833A (ja) | Syn−1,3−ジオール化合物の製造方法 | |
| EA016854B1 (ru) | Новый способ получения эфира 3-амино-5-фтор-4-диалкоксипентановой кислоты | |
| CN115626891A (zh) | 一种尼拉帕尼关键中间体的合成方法 | |
| HK1075659B (en) | A process for producing phenserine and its analog | |
| CN120271515A (zh) | 一种瑞司美替罗中间体的合成方法 | |
| JP2946678B2 (ja) | キラルなフェロセン誘導体 | |
| US5157138A (en) | Glutaric acid derivatives and preparation thereof | |
| KR20010009846A (ko) | 심바스타틴 제조에 유용한 중간체 및 그의 제조방법 | |
| JPS6140243A (ja) | 3,5−ジヒドロキシペンタノエ−トサブユニツトを有するHMG−CoAレダクタ−ゼ阻害剤の製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| A201 | Request for examination | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20060824 |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20061026 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20070313 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20061026 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |